Epizyme Inc.’s new chief executive Robert Bazemore understands the disease his company is targeting only too well. When he was introduced to employees this summer, Bazemore surprised them by disclosing that he’s a survivor of non-Hodgkin’s lymphoma, a life-threatening blood cancer that could potentially be treated by the company’s lead drug candidate.

https://www.bostonglobe.com/business/2015/12/04/epizyme-chief-executive-taking-aim-disease-that-threatened-his-life/nSxF37yUP5mGnLzHuNWZmI/story.html